To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
April 2014

Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone

Vol: 3| Issue: 4| Number:65| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4.

Contributing Authors:
P Barrett-Lee A Casbard J Abraham K Hood R Coleman P Simmonds H Timmins D Wheatley R Grieve G Griffiths N Murray

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

1404 patients with bone metastases from breast cancer were randomized to receive treatment with either oral ibandronic acid or intravenous zoledronic acid. The frequency and timing of skeletal-related events (SREs) was the primary non-inferiority endpoint. After 96 weeks of treatment, 50 mg of oral ibandronic acid given daily was inferior to 4 mg of intravenous zoledronic acid given every 4 weeks ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.

Continue